Targeting angiogenesis in childhood sarcomas

Sarcoma

Volumn 2011, Issue , 2011, Pages

  Houghton, Peter J ^a   Bid, Hemant K ^a  

^a NATIONWIDE CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENIC FACTOR; BEVACIZUMAB; CEDIRANIB; EVEROLIMUS; FIGITUMUMAB; PROTEIN TYROSINE KINASE INHIBITOR; RAPAMYCIN; RIDAFOROLIMUS; SOMATOMEDIN; SOMATOMEDIN RECEPTOR; SORAFENIB; SUNITINIB; TEMSIROLIMUS; VASCULOTROPIN;

ANGIOGENESIS; ANTIANGIOGENIC THERAPY; ANTINEOPLASTIC ACTIVITY; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER INHIBITION; CANCER STAGING; CANCER SURVIVAL; CHILDHOOD CANCER; CHILDHOOD SARCOMA; DRUG BIOAVAILABILITY; HUMAN; OSTEOSARCOMA; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN SECRETION; REVIEW; RHABDOMYOSARCOMA; SARCOMA; SIGNAL TRANSDUCTION; SOFT TISSUE SARCOMA;

EID: 79251589906     PISSN: 1357714X     EISSN: 13691643     Source Type: Journal    
DOI: 10.1155/2011/601514     Document Type: Review

References (104)

1. Lutsenko S. V., Kiselev S. M., Severin S. E., Molecular mechanisms of tumor angiogenesis Biochemistry 2003 68 3 286 300
2. de Castro Junior G., Puglisi F., de Azambuja E., El Saghir N. S., Awada A., Angiogenesis and cancer: a cross-talk between basic science and clinical trials (the "do ut des" paradigm) Critical Reviews in Oncology/Hematology 2006 59 1 40 50
3. Borst M.,. Die Lehre von den Geschwulsten mit einem mikroskopischen Atlas, 1902
4. Ribbert H., Das Karzinom des Menschen sein Bau. seine Wachstum, seine Entstehung 1904 Bonn, Germany Verlag von Freidrich Cohen
5. Goldacre R. J., Sylven B., On the access of blood-borne dyes to various tumour regions British Journal of Cancer 1962 16 306 322
6. Dillon P. W., Whalen T. V., Azizkhan R. G., Haase G. M., Coran A. G., King D. R., Smith M., Wiener E., Neonatal soft tissue sarcomas: the influence of pathology on treatment and survival Journal of Pediatric Surgery 1995 30 7 1038 1041
7. Spunt S. L., Skapek S. X., Coffin C. M., Pediatric nonrhabdomyosarcoma soft tissue sarcomas Oncologist 2008 13 6 668 678
8. Pisters P. W. T., O'Sullivan B., Maki R. G., Evidence-based recommendations for local therapy for soft tissue sarcomas Journal of Clinical Oncology 2007 25 8 1003 1008
9. Anderson P. M., Pearson M., Novel therapeutic approaches in pediatric and young adult sarcomas Current Oncology Reports 2006 8 4 310 315
10. Ordez J. L., Martins A. S., Osuna D., Madoz-Grpide J., de Alava E., Targeting sarcomas: therapeutic targets and their rational Seminars in Diagnostic Pathology 2008 25 4 304 316
11. Heymach J. V., Angiogenesis and antiangiogenic approaches to sarcomas Current Opinion in Oncology 2001 13 4 261 269
12. Kurmasheva R. T., Harwood F. C., Houghton P. J., Differential regulation of vascular endothelial growth factor by Akt and mammalian target of rapamycin inhibitors in cell lines derived from childhood solid tumors Molecular Cancer Therapeutics 2007 6 5 1620 1628
13. Gee M. F. W., Tsuchida R., Eichler-Jonsson C., Das B., Baruchel S., Malkin D., Vascular endothelial growth factor acts in an autocrine manner in rhabdomyosarcoma cell lines and can be inhibited with all-trans-retinoic acid Oncogene 2005 24 54 8025 8037
14. Pavlakovic H., Havers W., Schweigerer L., Multiple angiogenesis stimulators in a single malignancy: implications for anti-angiogenic tumour therapy Angiogenesis 2001 4 4 259 262
15. De Giovanni C., Melani C., Nanni P., Landuzzi L., Nicoletti G., Frabetti F., Griffoni C., Colombo M. P., Lollini P. L., Redundancy of autocrine loops in human rhabdomyosarcoma cells: induction of differentiation by suramin British Journal of Cancer 1995 72 5 1224 1229
16. Yamazaki K., Abe S., Takekawa H., Sukoh N., Watanabe N., Ogura S., Nakajima I., Isobe H., Inoue K., Kawakami Y., Tumor angiogenesis in human lung adenocarcinoma Cancer 1994 74 8 2245 2250
17. Maeda K., Chung Y. S., Takatsuka S., Ogawa Y., Sawada T., Yamashita Y., Onoda N., Kato Y., Nitta A., Arimoto Y., Kondo Y., Sowa M., Tumor angiogenesis as a predictor of recurrence in gastric carcinoma Journal of Clinical Oncology 1995 13 2 477 481
18. Drawer M. K., Quantitative microvessel density: a staging and prognostic marker for human prostatic carcinoma Cancer 1996 78 2 345 349
19. Gasparini G., Bonoldi E., Viale G., Verderio P., Boracchi P., Panizzoni G. A., Radaelli U., Di Bacco A., Guglielmi R. B., Bevilacqua P., Prognostic and predictive value of tumour angiogenesis in ovarian carcinomas International Journal of Cancer 1996 69 3 205 211
20. Yudoh K., Kanamori M., Ohmori K., Yasuda T., Aoki M., Kimura T., Concentration of vascular endothelial growth factor in the tumour tissue as a prognostic factor of soft tissue sarcomas British Journal of Cancer 2001 84 12 1610 1615
21. Kawauchi S., Fukuda T., Tsuneyoshi M., Angiogenesis does not correlate with prognosis or expression of vascular endothelial growth factor in synovial sarcomas Oncology Reports 1999 6 5 959 964
22. Tomlinson J., Barsky S. H., Nelson S., Singer S., Pezeshki B., Lee M. C., Eilber F., Nguyen M., Different patterns of angiogenesis in sarcomas and carcinomas Clinical Cancer Research 1999 5 11 3516 3522
23. Saenz N. C., Heslin M. J., Adsay V., Lewis J. J., Leung D. H., LaQuaglia M. P., Brennan M. F., Neovascularity and clinical outcome in high-grade extremity soft tissue sarcomas Annals of Surgical Oncology 1998 5 1 48 53
24. Comandone A., Boglione E., Berardengo A., Microvessel density (MVD) as a marker of neoangiogenesis: prognostic significance in correlation with grading and stage in adult soft tissue sarcomas (STS) of the extremities. A prospective study Proceedings of the American Society of Clinical Oncology (ASCO '03) 2003. article no. 3303A
25. Yoshida Y., Kurokawa T., Fukuno N., Nishikawa Y., Kamitani N., Kotsuji F., Markers of apoptosis and angiogenesis indicate that carcinomatous components play an important role in the malignant behavior of uterine carcinosarcoma Human Pathology 2000 31 12 1448 1454
26. Dvorak H. F., Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy Journal of Clinical Oncology 2002 20 21 4368 4380
27. Montesano R., Vassalli J. D., Baird A., Basic fibroblast growth factor induces angiogenesis in vitro Proceedings of the National Academy of Sciences of the United States of America 1986 83 19 7297 7301
28. Basilico C., Moscatelli D., The FGF family of growth factors and oncogenes Advances in Cancer Research 1992 59 115 165
29. Fuhrmann-Benzakein E., Ma M. N., Rubbia-Brandt L., Mentha G., Ruefenacht D., Sappino A. P., Pepper M. S., Elevated levels of angiogenic cytokines in the plasma of cancer patients International Journal of Cancer 2000 85 1 40 45
30. Pantschenko A. G., Pushkar I., Anderson K. H., Wang Y., Miller L. J., Kurtzman S. H., Barrows G., Kreutzer D. L., The interleukin-1 family of cytokines and receptors in human breast cancer: implications for tumor progression International Journal of Oncology 2003 23 2 269 284
31. Hatzi E., Murphy C., Zoephel A., Rasmussen H., Morbidelli L., Ahorn H., Kunisada K., Tontsch U., Klenk M., Yamauchi-Takihara K., Ziche M., Rofstad E. K., Schweigerer L., Fotsis T., N-myc oncogene overexpression down-regulates IL-6; evidence that IL-6 inhibits angiogenesis and suppresses neuroblastoma tumor growth Oncogene 2002 21 22 3552 3561
32. Lin Y., Huang R., Chen L., Li S., Shi Q., Jordan C., Huang R. P., Identification of interleukin-8 as estrogen receptor-regulated factor involved in breast cancer invasion and angiogenesis by protein arrays International Journal of Cancer 2004 109 4 507 515
33. Zhang YU. W., Su Y., Volpert O. V., Vande Woude G. F., Hepatocyte growth factor/scatter factor mediates angiogenesis through positive VEGF and negative thrombospondin 1 regulation Proceedings of the National Academy of Sciences of the United States of America 2003 100 22 12718 12723
34. Brizzi M. F., Battaglia E., Montrucchio G., Dentelli P., Del Sorbo L., Garbarino G., Pegoraro L., Camussi G., Thrombopoietin stimulates endothelial cell motility and neoangiogenesis by a platelet-activating factor-dependent mechanism Circulation Research 1999 84 7 785 796
35. Risau W., Mechanisms of angiogenesis Nature 1997 386 6626 671 674
36. Kaya M., Wada T., Akatsuka T., Kawaguchi S., Nagoya S., Shindoh M., Higashino F., Mezawa F., Okada F., Ish S. II, Vascular endothelial growth factor expression in untreated osteosarcoma is predictive of pulmonary metastasis and poor prognosis Clinical Cancer Research 2000 6 2 572 577
37. Ferrara N., Hillan K. J., Gerber H. P., Novotny W., Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer Nature Reviews Drug Discovery 2004 3 5 391 400
38. Jain R. K., Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy Science 2005 307 5706 58 62
39. Yang J. C., Haworth L., Sherry R. M., Hwu P., Schwartzentruber D. J., Topalian S. L., Steinberg S. M., Chen H. X., Rosenberg S. A., A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer New England Journal of Medicine 2003 349 5 427 434
40. Miller K. D., Chap L. I., Holmes F. A., Cobleigh M. A., Marcom P. K., Fehrenbacher L., Dickler M., Overmoyer B. A., Reimann J. D., Sing A. P., Langmuir V., Rugo H. S., Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer Journal of Clinical Oncology 2005 23 4 792 799
41. Crane C. H., Ellis L. M., Abbruzzese J. L., Amos C., Xiong H. Q., Ho L., Evans D. B., Tamm E. P., Ng C., Pisters P. W. T., Charnsangavej C., Delclos M. E., O'Reilly M., Lee J. E., Wolff R. A., Phase I trial evaluating the safety of bevacizumab with concurrent radiotherapy and capecitabine in locally advanced pancreatic cancer Journal of Clinical Oncology 2006 24 7 1145 1151
42. Benesch M., Windelberg M., Sauseng W., Witt V., Fleischhack G., Lackner H., Gadner H., Bode U., Urban C., Compassionate use of bevacizumab (Avastin) in children and young adults with refractory or recurrent solid tumors Annals of Oncology 2008 19 4 807 813
43. Wong C., Wellman T. L., Lounsbury K. M., VEGF and HIF-1 expression are increased in advanced stages of epithelial ovarian cancer Gynecologic Oncology 2003 91 3 513 517
44. Han H., Silverman J. F., Santucci T. S., Macherey R. S., D'Amato T. A., Tung M. Y., Weyant R. J., Landreneau R. J., Vascular endothelial growth factor expression in stage I non-small cell lung cancer correlates with neoangiogenesis and a poor prognosis Annals of Surgical Oncology 2001 8 1 72 79
45. Manning G., Whyte D. B., Martinez R., Hunter T., Sudarsanam S., The protein kinase complement of the human genome Science 2002 298 5600 1912 1934
46. Kim A., Balis F. M., Widemann B. C., Sorafenib and sunitinib Oncologist 2009 14 8 800 805
47. Grandinetti C. A., Goldspiel B. R., Sorafenib and sunitinib: novel targeted therapies for renal cell cancer Pharmacotherapy 2007 27 8 1125 1144
48. Keir S. T., Maris J. M., Lock R., Initial testing (stage 1) of the multi-targeted kinase inhibitor sorafenib by the pediatric preclinical testing program Pediatric Blood Cancer 2010 55 6 1126 1133
49. Maris J. M., Courtright J., Houghton P. J., Morton C. L., Kolb E. A., Lock R., Tajbakhsh M., Reynolds C. P., Keir S. T., Wu J., Smith M. A., Initial testing (stage 1) of sunitinib by the pediatric preclinical testing program Pediatric Blood and Cancer 2008 51 1 42 48
50. Wedge S. R., Kendrew J., Hennequin L. F., Valentine P. J., Barry S. T., Brave S. R., Smith N. R., James N. H., Dukes M., Curwen J. O., Chester R., Jackson J. A., Boffey S. J., Kilburn L. L., Barnett S., Richmond G. H. P., Wadsworth P. F., Walker M., Bigley A. L., Taylor S. T., Cooper L., Beck S., Jörgensmeier J. M., Ogilvie D. J., AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer Cancer Research 2005 65 10 4389 4400
51. Maris J. M., Courtright J., Houghton P. J., Morton C. L., Gorlick R., Kolb E. A., Lock R., Tajbakhsh M., Reynolds C. P., Keir S. T., Wu J., Smith M. A., Initial testing of the VEGFR inhibitor AZD2171 by the Pediatric Preclinical Testing Program Pediatric Blood and Cancer 2008 50 3 581 587
52. Drevs J., Siegert P., Medinger M., Mross K., Strecker R., Zirrgiebel U., Harder J., Blum H., Robertson J., Jörgensmeier J. M., Puchalski T. A., Young H., Saunders O., Unger C., Phase I clinical study of AZD2171, an oral vascular endothelial growth factor signaling inhibitor, in patients with advanced solid tumors Journal of Clinical Oncology 2007 25 21 3045 3054
53. Batchelor T. T., Sorensen A. G., di Tomaso E., Zhang W. T., Duda D., Cohen K. S., Kozak K. R., Cahill D. P., Chen P. J., Zhu M., Ancukiewicz M., Mrugala M. M., Plotkin S., Drappatz J., Louis D. N., Ivy P., Scadden D., Benner T., Loeffler J. S., Wen P. Y., Jain R. K., AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients Cancer Cell 2007 11 1 83 95
54. Reichardt P., Lindner T., Pink D., Thuss-Patience P. C., Kretzschmar A., Drken B., Chemotherapy in alveolar soft part sarcomas: what do we know? European Journal of Cancer 2003 39 11 1511 1516
55. Gardner K., Judson I., Leahy M., Activity of cediranib, a highly potent and selective VEGF signaling inhibitor, in alveolar soft part sarcoma Journal of Clinical Oncology 2009 27 15S. article no. 10523A
56. Houghton P. J., Morton C. L., Kolb E. A., Gorlick R., Lock R., Carol H., Reynolds C. P., Maris J. M., Keir S. T., Billups C. A., Smith M. A., Initial testing (stage 1) of the mTOR inhibitor rapamycin by the pediatric preclinical testing program Pediatric Blood and Cancer 2008 50 4 799 805
57. Humar R. O. K., Kiefer F. N., Berns H., Resink T. J., Battegay E. J., Hypoxia enhances vascular cell proliferation and angiogenesis in vitro via rapamycin (mTOR)-dependent signaling FASEB Journal 2002 16 8 771 780
58. Guba M., Von Breitenbuch P., Steinbauer M., Koehl G., Flegel S., Hornung M., Bruns C. J., Zuelke C., Farkas S., Anthuber M., Jauch K. W., Geissler E. K., Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor Nature Medicine 2002 8 2 128 135
59. lvarez-Garca., Garca-López E., Loredo V., Gil-Pea H., Rodrguez-Surez J., Ordez F. A., Carbajo-Pérez E., Santos F., Rapamycin induces growth retardation by disrupting angiogenesis in the growth plate Kidney International 2010 78 6 561 568
60. Kurmasheva R. T., Dudkin L., Billups C., Debelenko L. V., Morton C. L., Houghton P. J., The insulin-like growth factor-1 receptor-targeting antibody, CP-751,871, suppresses tumor-derived VEGF and synergizes with rapamycin in models of childhood sarcoma Cancer Research 2009 69 19 7662 7671
61. Benini S., Zuntini M., Manara M. C., Cohen P., Nicoletti G., Nanni P., Oh Y., Picci P., Scotlandi K., Insulin-like growth factor binding protein 3 as an anticancer molecule in Ewing's sarcoma International Journal of Cancer 2006 119 5 1039 1046
62. Granata R., Trovato L., Garbarino G., Taliano M., Ponti R., Sala G., Ghidoni R., Ghigo E., Dual effects of IGFBP-3 on endothelial cell apoptosis and survival: involvement of the sphingolipid signaling pathways FASEB Journal 2004 18 12 1456 1458
63. Liu B., Lee K. W., Anzo M., Zhang B., Zi X., Tao Y., Shiry L., Pollak M., Lin S., Cohen P., Insulin-like growth factor-binding protein-3 inhibition of prostate cancer growth involves suppression of angiogenesis Oncogene 2007 26 12 1811 1819
64. Rho S. B., Dong S. M., Kang S., Seo S. S., Yoo C. W., Lee D. O., Woo J. S., Park S. Y., Insulin-like growth factor-binding protein-5 (IGFBP-5) acts as a tumor suppressor by inhibiting angiogenesis Carcinogenesis 2008 29 11 2106 2111
65. Hwa V., Oh Y., Rosenfeld R. G., Insulin-like growth factor binding proteins: a proposed superfamily Acta Paediatrica 1999 88 428 37 45
66. Collet C., Candy J., How many insulin-like growth factor binding proteins? Molecular and Cellular Endocrinology 1998 139 1-2 1 6
67. Gallicchio M. A., Kneen M., Hall C., Scott A. M., Bach L. A., Overexpression of insulin-like growth factor binding protein-6 inhibits rhabdomyosarcoma growth in vivo International Journal of Cancer 2001 94 5 645 651
68. Kurmasheva R. T., Houghton P. J., IGF-I mediated survival pathways in normal and malignant cells Biochimica et Biophysica Acta 2006 1766 1 1 22
69. Minniti C. P., Tsokos M., Newton W. A., Helman L. J., Specific expression of insulin-like growth factor-II in rhabdomyosarcoma tumor cells American Journal of Clinical Pathology 1994 101 2 198 203
70. El-Badry O. M., Minniti C., Kohn E. C., Houghton P. J., Daughaday W. H., Helman L. J., Insulin-like growth factor II acts as an autocrine growth and motility factor in human rhabdomyosarcoma tumors Cell Growth Differentiation 1990 1 7 325 331
71. Owen L. A., Lessnick S. L., Identification of target genes in their native cellular context: an analysis of EWS/FLI in Ewing's sarcoma Cell Cycle 2006 5 18 2049 2053
72. Scotlandi K., Benini S., Sarti M., Serra M., Lollini P. L., Maurici D., Picci P., Manara M. C., Baldini N., Insulin-like growth factor I receptor-mediated circuit in Ewing's sarcoma/peripheral neuroectodermal tumor: a possible therapeutic target Cancer Research 1996 56 20 4570 4574
73. Yee D., Favoni R. E., Lebovic G. S., Lombana F., Powell D. R., Reynolds C. P., Rosen N., Insulin-like growth factor I expression by tumors of neuroectodermal origin with the t(11;22) chromosomal translocation. A potential autocrine growth factor Journal of Clinical Investigation 1990 86 6 1806 1814
74. Calle E. E., Kaaks R., Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms Nature Reviews Cancer 2004 4 8 579 591
75. Kappel C. C., Velez-Yanguas M. C., Hirschfeld S., Helman L. J., Human osteosarcoma cell lines are dependent on insulin-like growth factor I for in vitro growth Cancer Research 1994 54 10 2803 2807
76. Anders Kolb E., Gorlick R., Houghton P. J., Morton C. L., Lock R., Carol H., Patrick Reynolds C., Maris J. M., Keir S. T., Billups C. A., Smith M. A., Initial testing (stage 1) of a monoclonal antibody (SCH 717454) against the IGF-1 receptor by the pediatric preclinical testing program Pediatric Blood and Cancer 2008 50 6 1190 1197
77. Burrow S., Andrulis I. L., Pollak M., Bell R. S., Expression of insulin-like growth factor receptor, IGF-1, and IGF-2 in primary and metastatic osteosarcoma Journal of Surgical Oncology 1998 69 1 21 27
78. Feng Y., Dimitrov D. S., Monoclonal antibodies against components of the IGF system for cancer treatment Current Opinion in Drug Discovery and Development 2008 11 2 178 185
79. Kalebic T., Tsokos M., Helman L. J., In vivo treatment with antibody against IGF-1 receptor suppresses growth of human rhabdomyosarcoma and down-regulates p34(cdc2) Cancer Research 1994 54 21 5531 5534
80. Anders Kolb E., Gorlick R., Houghton P. J., Morton C. L., Lock R., Carol H., Patrick Reynolds C., Maris J. M., Keir S. T., Billups C. A., Smith M. A., Initial testing (stage 1) of a monoclonal antibody (SCH 717454) against the IGF-1 receptor by the pediatric preclinical testing program Pediatric Blood and Cancer 2008 50 6 1190 1197
81. Kolb E. A., Kamara D., Zhang W., Lin J., Hingorani P., Baker L., Houghton P., Gorlick R., R1507, a fully human monoclonal antibody targeting IGF-1R, is effective alone and in combination with rapamycin in inhibiting growth of osteosarcoma xenografts Pediatric Blood and Cancer 2010 55 1 67 75
82. Wang Y., Lipari P., Wang X., Hailey J., Liang L., Ramos R., Liu M., Pachter J. A., Bishop W. R., Wang Y., A fully human insulin-like growth factor-I receptor antibody SCH 717454 (robatumumab) has antitumor activity as a single agent and in combination with cytotoxics in pediatric tumor xenografts Molecular Cancer Therapeutics 2010 9 2 410 418
83. Weinstein I. B., Joe A. K., Mechanisms of Disease: oncogene addictiona rationale for molecular targeting in cancer therapy Nature Clinical Practice Oncology 2006 3 8 448 457
84. Easton J. B., Kurmasheva R. T., Houghton P. J., IRS-1: auditing the effectiveness of mTOR inhibitors Cancer Cell 2006 9 3 153 155
85. Huang S., Shu L., Dilling M. B., Easton J., Harwood F. C., Ichijo H., Houghton P. J., Sustained activation of the JNK cascade and rapamycin-induced apoptosis are suppressed by p53/p21 Molecular Cell 2003 11 6 1491 1501
86. Thimmaiah K. N., Easton J., Huang S., Veverka K. A., Germain G. S., Harwood F. C., Houghton P. J., Insulin-like growth factor i-mediated protection from rapamycin-induced apoptosis is independent of Ras-Erk1-Erk2 and phosphatidylinositol 3′-kinase-Akt signaling pathways Cancer Research 2003 63 2 364 374
87. Dilling M. B., Dias P., Shapiro D. N., Germain G. S., Johnson R. K., Houghton P. J., Rapamycin selectively inhibits the growth of childhood rhabdomyosarcoma cells through inhibition of signaling via the type I insulin-like growth factor receptor Cancer Research 1994 54 4 903 907
88. Feng Y., Zhu Z., Xiao X., Choudry V., Barrett J. C., Dimitrov D. S., Novel human monoclonal antibodies to insulin-like growth factor (IGF)-II that potently inhibit the IGF receptor type I signal transduction function Molecular Cancer Therapeutics 2006 5 1 114 120
89. Rodon J., Patnaik A., Stein M., A phase I man monoclonal antibody IGF-1R antagonist in patients with advanced cancer Journal of Clinical Oncology 2007 18S. article no. 3590A
90. Higano C. S., Yu E. Y., Whiting S. H., A phase I, first in man study of weekly IMC-A12, a fully human insulin like growth factor-1 receptor IgG1 monoclonal antibody, in patients with advanced solid tumors Journal of Clinical Oncology 2007 25 18S. article no. 3505A
91. Tolcher A. W., Rothenberg M. L., Rodon J., A phase I pharmacokinetic and pharmacodynamic study of AMG 479, a fully human monoclonal antibody against insulin-like growth factor type 1 receptor (IGF-1R), in advanced solid tumors Journal of Clinical Oncology 2007 25 18S. article no. 3002A
92. Atorzi F., Tabernero J., Cervantes A., A phase I, pharmacokinetic (PK) and pharmacodynamic (PD) study of weekly (qW) MK-0646, an insulin-like growth factor-1 receptor (IGF1R) monoclonal antibody (MAb) in patients (pts) with advanced solid tumors Journal of Clinical Oncology 2008 26 15S. article no. 3519A
93. Atzori F., Tabernero J., Cervantes A., A phase I, pharmacokinetic (PK) and pharmacodynamic (PD) study of weekly (qW) MK-0646, an insulin-like growth factor-1 receptor (IGF1R) monoclonal antibody (MAb) in patients (pts) with advanced solid tumors Journal of Clinical Oncology 2008 26 15S. article no. 3519A
94. Carmeliet P., Mechanisms of angiogenesis and arteriogenesis Nature Medicine 2000 6 4 389 395
95. Risau W., Flamme I., Vasculogenesis Annual Review of Cell and Developmental Biology 1995 11 73 91
96. Lee T. H., Bolontrade M. F., Worth L. L., Guan H., Ellis L. M., Kleinerman E. S., Production of VEGF165 by Ewing's sarcoma cells induces vasculogenesis and the incorporation of CD34 stem cells into the expanding tumor vasculature International Journal of Cancer 2006 119 4 839 846
97. Guleng B., Tateishi K., Ohta M., Kanai F., Jazag A., Ijichi H., Tanaka Y., Washida M., Morikane K., Fukushima Y., Yamori T., Tsuruo T., Kawabe T., Miyagishi M., Taira K., Sata M., Omata M., Blockade of the stromal cell-derived factor-1/CXCR4 axis attenuates in vivo tumor growth by inhibiting angiogenesis in a vascular endothelial growth factor-independent manner Cancer Research 2005 65 13 5864 5871
98. Reddy K., Zhou Z., Jia S. F., Lee T. H., Morales-Arias J., Cao Y., Kleinerman E. S., Stromal cell-derived factor-1 stimulates vasculogenesis and enhances Ewing's sarcoma tumor growth in the absence of vascular endothelial growth factor International Journal of Cancer 2008 123 4 831 837
99. Lindsay C. R., MacPherson I. R. J., Cassidy J., Current status of cediranib: the rapid development of a novel anti-angiogenic therapy Future Oncology 2009 5 4 421 432
100. Teicher B. A., Holden S. A., Ara G., Dupuis N. P., Liu F., Yuan J., Ikebe M., Kakeji Y., Influence of an anti-angiogenic treatment on 9L gliosarcoma: oxygenation and response to cytotoxic therapy International Journal of Cancer 1995 61 5 732 737
101. Teicher B. A., Holden S. A., Ara G., Dupuis N. P., Goff D., Restoration of tumor oxygenation after cytotoxic therapy by a perflubron emulsion/carbogen breathing The Cancer Journal from Scientific American 1995 1 1 43 48
102. Teicher B. A., Role of angiogenesis in the response to anticancer therapies Drug Resistance Updates 1998 1 1 59 61
103. Devineni D., Klein-Szanto A., Gallo J. M., Uptake of temozolomide in a rat glioma model in the presence and absence of the angiogenesis inhibitor TNP-470 Cancer Research 1996 56 9 1983 1987
104. Dickson P. V., Hamner J. B., Sims T. L., Fraga C. H., Ng C. Y. C., Rajasekeran S., Hagedorn N. L., McCarville M. B., Stewart C. F., Davidoff A. M., Bevacizumab-induced transient remodeling of the vasculature in neuroblastoma xenografts results in improved delivery and efficacy of systemically administered chemotherapy Clinical Cancer Research 2007 13 13 3942 3950